Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHMSA Ilaris Coverage Prior Auth Policy | OpenPayer
    Ask Trek AI about this page
    CurrentHawaii Medical Service Association (HMSA)Policy N/A

    Ilaris (canakinumab) Coverage and Prior Authorization

    Customize your policy alerts

    Sign up for all Hawaii Medical Service Association (HMSA) policy alerts

    Know when Hawaii Medical Service Association (HMSA) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs HMSA Medicare Advantage coverage and precertification for Ilaris (canakinumab) used for specified autoinflammatory diseases, Still's disease, and gout flares. Coverage requires approval criteria for initial therapy, and reauthorization requires ongoing treatment benefit.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyIlaris (canakinumab) Coverage and Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateJune 26, 2026
    Last ReviewApr 1, 2026
    Next Review DateNot specified
    Key ActionPrecertification is required for Ilaris; providers should use the fax form available through the HMSA medical specialty drug policy website.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    7Covered indication categories
    12 monthsAuthorization period
    Age 4+Minimum age for CAPS
    Age 2+Minimum age for Still's disease and sJIA

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    RequiredPrecertification

    Covered Indications

    Cryopyrin-associated periodic syndromes

    Authorization of 12 months may be granted when the member is being treated for CAPS.

    CAPS: The member has cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome or Muckle-Wells syndrome.Age 4 years or older where applicable

    Tumor necrosis factor receptor associated periodic syndrome

    Authorization of 12 months may be granted when the member is being treated for TRAPS.

    TRAPS: The member has tumor necrosis factor receptor associated periodic syndrome.

    Hyperimmunoglobulin D syndrome or mevalonate kinase deficiency

    Authorization of 12 months may be granted when the member is being treated for HIDS or MKD.

    HIDS/MKD: The member has hyperimmunoglobulin D syndrome or mevalonate kinase deficiency.

    Familial Mediterranean Fever

    Authorization of 12 months may be granted when the member is being treated for FMF.

    FMF: The member has familial Mediterranean fever.

    Systemic juvenile idiopathic arthritis

    Authorization of 12 months may be granted when the member is being treated for active systemic juvenile idiopathic arthritis.

    sJIA: The member has active systemic juvenile idiopathic arthritis.

    Active adult-onset Still's disease

    Authorization of 12 months may be granted when the member is being treated for active adult-onset Still's disease.

    AOSD: The member has active adult-onset Still's disease.

    Gout flares

    Authorization of 12 months may be granted when the member is being treated for gout flares.

    Gout flare treatment: The member has gout flares and has had an inadequate response, intolerance, or contraindication to non-steroidal anti-inflammatory drugs, colchicine, and corticosteroids.

    All three alternative therapies are addressed in the criterion.

    Continuation therapy

    An additional 12 months may be granted for continuation therapy when all criteria are met.

    Reauthorization: The member is currently receiving therapy with Ilaris; Ilaris is being used to treat an indication in the coverage criteria section; and the member is receiving benefit from therapy as evidenced by low disease activity or improvement in signs and symptoms of the condition.

    Applies to members previously authorized by HMSA/CVS.

    Initial Authorization Requirements

    CAPS — Initial Therapy Criteria

    Authorization of 12 months may be granted.

    CAPS: Treatment is for cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome or Muckle-Wells syndrome.Age 4 years or older where applicable

    TRAPS — Initial Therapy Criteria

    Authorization of 12 months may be granted.

    TRAPS: Treatment is for tumor necrosis factor receptor associated periodic syndrome.

    HIDS/MKD — Initial Therapy Criteria

    Authorization of 12 months may be granted.

    Reauthorization Requirements

    Ilaris reauthorization

    Authorization of an additional 12 months may be granted to members previously authorized by HMSA/CVS when all criteria are met.

    Continuation requirements

    • The member is currently receiving therapy with Ilaris.
    • Ilaris is being used to treat an indication in the coverage criteria section.
    • The member is receiving benefit from therapy as evidenced by low disease activity or improvement in signs and symptoms of the condition.

    No previous authorization

    Members without previous authorization or precertification, including new members and members currently receiving treatment without prior authorization, must meet initial approval criteria.

    Gout Flare Treatment Alternatives

    StepRequirementFailure criteria
    1For gout flares, the member must have tried or be unable to use NSAIDs, colchicine, and corticosteroids.Inadequate response, intolerance, or contraindication to NSAIDs, colchicine, and corticosteroids.

    Precertification and Coverage Risks

    Prior Authorization

    Precertification Required

    Precertification is required. Refer to the HMSA medical specialty drug policy website for the required fax form.

    Denial Risk

    Indication and Exclusion Risks

    Coverage is available only when all approval criteria are met and the member has no exclusions to the prescribed therapy. Requests that do not meet the applicable indication criteria or that involve an exclusion may be denied.

    Step Therapy

    Failure of Gout Flare Alternatives

    Coverage for treatment of gout flares requires documentation that the member has had an inadequate response, intolerance, or contraindication to each of the following alternatives: NSAIDs, colchicine, and corticosteroids.

    Drug Quantity and Dosing Limits

    Quantity Limits
    MedicationIlaris (canakinumab)
    Dosing limitsMay apply
    Basis for limitsFDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines

    Policy Context

    Ilaris (canakinumab) is covered for specified periodic fever syndromes, including CAPS, TRAPS, HIDS/MKD, and familial Mediterranean fever; for active Still's disease, including adult-onset Still's disease and systemic juvenile idiopathic arthritis; and for selected gout flares when the applicable coverage criteria are met. Initial authorization may be granted for 12 months.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyIlaris (canakinumab) Coverage and Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateJune 26, 2026
    Last ReviewApr 1, 2026
    Next Review DateNot specified
    Key ActionPrecertification is required for Ilaris; providers should use the fax form available through the HMSA medical specialty drug policy website.
    SourceLink
    On This Page
    Covered IndicationsInitial Authorization RequirementsReauthorization RequirementsGout Flare Treatment AlternativesPrecertification and Coverage RisksDrug Quantity and Dosing LimitsPolicy Context
    HIDS/MKD: Treatment is for hyperimmunoglobulin D syndrome or mevalonate kinase deficiency.

    Familial Mediterranean Fever — Initial Therapy Criteria

    Authorization of 12 months may be granted.

    FMF: Treatment is for familial Mediterranean fever.

    Systemic juvenile idiopathic arthritis — Initial Therapy Criteria

    Authorization of 12 months may be granted.

    sJIA: Treatment is for active systemic juvenile idiopathic arthritis.

    Active adult-onset Still's disease — Initial Therapy Criteria

    Authorization of 12 months may be granted.

    AOSD: Treatment is for active adult-onset Still's disease.

    Gout flares — Initial Therapy Criteria

    Authorization of 12 months may be granted.

    Gout flares: Treatment is for gout flares and the member has had an inadequate response, intolerance, or contraindication to non-steroidal anti-inflammatory drugs, colchicine, and corticosteroids.
    No previous authorization: The member must meet the applicable initial therapy criteria in section B.
    • Authorization may be granted for 12 months when these requirements are met.